Our Studies

See below for a current list of our ongoing studies.


Currently Enrolling Participants

The SUVN-502 Study is a research study testing whether an investigational medication, SUVN-502 can help with memory and other symptoms of Alzheimer’s disease. This Study is Currently Enrolling Participants:

The SUVN-502 Study will involve approximately 530 people with moderate stage Alzheimer’s disease across 90 US study centers. You, or someone you care for, may participate, if you:

    • Are between 50 to 85 years of age
    • Have Alzheimer’s disease for at least 1 year
    • Are currently receiving treatment with Aricept® and Namenda® or Namenda XR® or the combination product, Namzaric®
    • Have a friend or relative willing to be your study partner throughout the study.

ADVANCE Clinical Trial

Currently Enrolling Participants

Alzheimer’s with Agitation

The purpose of the study is to determine the safety and effectiveness of an investigational medication for agitation in patients with Alzheimer’s disease. This Study is Currently Enrolling Participants:

Who may qualify.
The ADVANCE Study is open to those who meet the following criteria:

      • Are 65 to 90 years of age
      • Have a diagnosis of probable Alzheimer’s disease
      • Have a diagnosis of clinically significant agitation
      • Have a caregiver who is willing and able to comply with the study instructions

Study schedule.
Participants in the ADVANCE Study will:

      • Attend six in-office visits and one follow-up visit over the phone
      • Receive the study drug twice daily for five weeks

Caregivers in the ADVANCE Study will need to:

      • Accompany the participant to all study visits
      • Complete a brief daily diary

Teens and Young Adults Depression Study

Currently Enrolling Participants

We are conducting a clinical study investigating a non-drug therapy that may help with teens/young adults depression. This Study is Currently Enrolling Participants:

      • Who are 12 to 21 years old
      • Who have diagnosed with depression
      • Not satisfied with anti-depressant medication
      • Experiencing depression lasting more than 4 weeks and less than 3 years

Study participants will receive:

      • No-cost treatment of an investigational non-drug treatment for depression in teens and young adults

The non-drug treatment has been FDA-cleared for adults (22-70 years of age). This trial will be investigating the safety and efficacy of this treatment in teens/young adults.


Sprites Study

Not Currently Enrolling 

Has your child recently started sertraline, received a new sertraline prescription or recently started psychotherapy to treat their psychiatric condition?

If so, you may be interested in a long-term study called SPRITES that is being conducted to learn about how sertraline or psychotherapy affects aspects of cognitive, emotional, and physical development in children. This study will find out more information about the long term effects that sertraline may have on developing children and adolescents.


Hummingbird Postpartum Depression Trial

Not Currently Enrolling 

The Hummingbird Study is a research study evaluating an investigational medication in women with moderate to severe postpartum depression.

Who can participate?

To be considered for the study, participants must be:

      • Between 18 – 45 years old
      • Gave birth within the last 6 months
      • Frequently feel extremely sad, anxious or overwhelmed and these symptoms are associated with postpartum depression

Additional Study Information and references:

Postpartum depression is a biological complication of pregnancy. 

During pregnancy, levels of certain hormones rise and then rapidly fall after giving birth1. However, in some women, these hormone shifts may contribute to postpartum depression. You are not alone. Up to 20% of women experience postpartum depression following childbirth2.

Postpartum depression symptoms may include:

      • Feelings of sadness, tearfulness, emptiness or hopelessness
      • Angry outbursts, irritability or frustration, even over small matters
      • Anxiety, agitation or restlessness
      • Loss of interest or pleasure in most or all normal activities
      • Changes in appetite
      • Feelings of worthlessness or guilt, fixating on past failures or blaming yourself for things that aren’t your responsibility
      • Trouble bonding with your baby
      • Thoughts of harming yourself or your baby
      1. National Institute of Mental Health. Postpartum Depression Facts. http://www.nimh.nih.gov/health/publications/postpartum-depression-facts/index.shtml. Accessed September 28, 2016.
      2. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106:1071-83.

Evaluating Gait and Balance in Subjects with Dementia

Not Currently Enrolling 

This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer’s DiseaseDementia with Lewy Bodies or Parkinson’s Disease Dementia.

Who can participate?

To be considered for the study, participants must be:

      • Male or female subject with a clinical diagnosis of Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), or Parkinson’s disease dementia (PDD).
      • Age 50-89
      • Subjects must be on stable background acetylcholinesterase inhibitor therapy (i.e. Donepezil, Aricept, Namenda, Memantine, etc)
      • Accompanied by a caregiver or someone who can oversee the participant’s study involvement and answer questions about how the participant is feeling and functioning
      • History of gait impairment (i.e. walking and balance issues, such as falls)

PrecisionMed Trial

Not Currently Enrolling


Alzheimer’s Disease and Mild Cognitive Impairment
As part of a paid research study, we are conducting cognitive and other testing on volunteers aged 50 years and older who have been diagnosed with Mild Alzheimer’s Disease or Mild Cognitive Impairment.


Mindset Study

Not Currently Enrolling

Alzheimer’s Disease
MINDSET is a Phase III clinical research program evaluating an investigational medication, RVT-101, for the treatment of mild-to-moderate Alzheimer’s disease. Researchers are investigating how effective the combination of RVT-101 with donepezil will be in helping patients’ cognition and ability to perform daily living activities, as compared with donepezil alone. The study plans to enroll 1,150 participants worldwide.

Who can participate?

To be considered for the study, participants must be:

      • Experiencing memory loss or diagnosed with Alzheimer’s disease or dementia*
      • Age 50-85
      • Taking donepezil

Accompanied by a caregiver or someone who can oversee the participant’s study involvement and answer questions about how the participant is feeling and functioning